Abstract
To evaluate the safety and efficacy of a gadoterate meglumine formulation as an oral contrast agent, MRI (0.5 T) was performed on 29 patients with abdominal disease before and after administration of contrast material. The patients ingested 16 ml/kg of a gadoterate meglumine solution (10 g/l glucose, 2 mmol/l gadoterate meglumine) over 1 h. Fourteen per cent of patients had mild side effects related to the contrast agent. Significant hyperintense contrast enhancement was achieved for the stomach and duodenum allowing better delineation of gastric and duodenal walls, entire pancreas and spleen on T1- and T2-weighted spin echo sequences. In 5 patients more diagnostic information was available from post-contrast images compared with precontrast images. This study shows that gadoterate meglumine is a safe and well-tolerated contrast agent that improves MRI of the proximal gastrointestinal tract and upper abdomen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Laniado M, Kornmesser W, Hamm B, Clauss W, Weinmann HJ, Felix R (1988) MR imaging of the gastrointestinal tract: value of Gd-DTPA. AJR 150: 817–821
Kaminsky S, Laniado M, Gogoll M, Kornmesser W, Clauss W, Langer M, Claussen C, Felix R (1991) Gadopentate dimeglumine as a bowel contrast agent: safety and efficacy. Radiology 178: 503–508
Wesbey GE, Brasch RC, Goldberg HI, Engelstad BL, Moss AA (1985) Dilute oral iron solutions as gastrointestinal contrast agents for magnetic resonance imaging: initial clinical experience. Magn Reson Imaging 3: 57–64
Hahn PF, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, Fretz CJ, Ferrucci JT (1990) First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 175: 695–700
Rinck PA, Smevik O, Nilsen G, Klepp O, Onsrud M, Oksendal A, Borseth A (1991) Oral magnetic particles in MR imaging of the abdomen and pelvis. Radiology 178: 775–779
Ros PR, Steinman RM, Torres GM, Burton SS, Panaccione JL, Rappaport DC, McGorray SP (1991) The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers. AJR 157: 761–767
Kramer MS, Feinstein AR (1981) Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Thern 29: 111–123
Doucet D, Brelet F, Josipowicz N, Bonnemain B (1987) Study of Gd-DOTA, orally administered in rats (abstract). In: Book of abstracts: Premier congrès sur la recherche en imagerie médicale, Paris. CERF/CEB, Paris, p 35
Schwizer W, Maecke H, Fried M (1992) Measurement of gastric emptying by magnetic resonance imaging in humans. Gastroenterology 103: 369–376
Runge VM, Tweedle MF, Zirger AJ, Price AC, Clanton JA, Whelan HT (1986) A comparison of gadolinium DOTA and DTPA. Invest Radiol 26: 5–16
Cory DA, Schwartentruber DJ, Mock BH (1987) Ingested manganese chloride as a contrast agent for magnetic resonance imaging. Magn Reson Imaging 5: 65–70
Laniado M, Kaminsky S (1990) Enteral contrast agents for improved MRI of the abdomen: Gd-DTPA versus negative contrast enhancement. In: contrast media in MRI. International Workshop, Berlin. Medicom Europe B. V., pp 63–68
Author information
Authors and Affiliations
Additional information
Correspondence to: Y. Miaux
Rights and permissions
About this article
Cite this article
Miaux, Y., Frija, J., Cyna-Gorse, F. et al. The value of gadoterate meglumine as a gastrointestinal contrast agent in MRI. Eur. Radiol. 3, 248–252 (1993). https://doi.org/10.1007/BF00425903
Issue Date:
DOI: https://doi.org/10.1007/BF00425903